Current smoker | Ex-smoker | |||||
---|---|---|---|---|---|---|
GLY (n = 251) | Placebo (n = 245) | Total (N = 496) | GLY (n = 186) | Placebo (n = 185) | Total (N = 371) | |
Age, years, median (range) | 61.0 (44, 83) | 60.0 (41, 84) | 60.0 (41, 84) | 68.0 (43, 86) | 67.0 (48, 87) | 67.0 (43, 87) |
Male, n (%) | 142 (56.6) | 151 (61.6) | 293 (59.1) | 109 (58.6) | 102 (55.1) | 211 (56.9) |
Race, n (%) | ||||||
Caucasian | 223 (88.8) | 207 (84.5) | 430 (86.7) | 172 (92.5) | 166 (89.7) | 338 (91.1) |
Black | 22 (8.8) | 35 (14.3) | 57 (11.5) | 8 (4.3) | 11 (5.9) | 19 (5.1) |
Asian | 1 (0.4) | 0 | 1 (0.2) | 2 (1.1) | 3 (1.6) | 5 (1.3) |
Native American | 2 (0.8) | 2 (0.8) | 4 (0.8) | 0 | 2 (1.1) | 2 (0.5) |
Other | 3 (1.2) | 1 (0.4) | 4 (0.8) | 4 (2.2) | 3 (1.6) | 7 (1.9) |
Duration of COPD, years, median (range) | 4.7 (0.0, 19.0) | 4.9 (0.0, 29.9) | 4.8 (0.0, 29.9) | 6.1 (0.0, 28.6) | 6.0 (0.0, 32.6) | 6.0 (0.0, 32.6) |
Airflow obstruction (GOLD 2011 [16]), n (%) | ||||||
Mild (GOLD 1) | 0 | 1 (0.4) | 1 (0.2) | 0 | 0 | 0 |
Moderate (GOLD 2) | 166 (66.1) | 165 (67.3) | 331 (66.7) | 111 (59.7) | 102 (55.1) | 213 (57.4) |
Severe (GOLD 3) | 83 (33.1) | 75 (30.6) | 158 (31.9) | 72 (38.7) | 81 (43.8) | 153 (41.2) |
Missing | 2 (0.8) | 4 (1.6) | 6 (1.2) | 3 (1.6) | 2 (1.1) | 5 (1.3) |
Combined assessment of COPD (GOLD 2011 [16]), n (%) | ||||||
Group A | 1 (0.4) | 0 | 1 (0.2) | 0 | 1 (0.5) | 1 (0.3) |
Group B | 161 (64.1) | 157 (64.1) | 318 (64.1) | 108 (58.1) | 94 (50.8) | 202 (54.4) |
Group C | 0 | 0 | 0 | 0 | 0 | 0 |
Group D | 87 (34.7) | 84 (34.3) | 171 (34.5) | 75 (40.3) | 88 (47.6) | 163 (43.9) |
Missing | 2 (0.8) | 4 (1.6) | 6 (1.2) | 3 (1.6) | 2 (1.1) | 5 (1.3) |
Estimated number of pack-years, median (range) | 46.0 (10.0, 146.5) | 48.0 (11.0, 184.0) | 47.0 (10.0, 184.0) | 46.0 (12.5, 240.0) | 49.0 (10.0, 156.0) | 47.0 (10.0, 240.0) |
ICS use at baseline, n (%) | 56 (22.3) | 66 (26.9) | 122 (24.6) | 65 (34.9) | 65 (35.1) | 130 (35.0) |
Pre-bronchodilator FEV1, mean (SD) | ||||||
Volume, L | 1.3 (0.5) | 1.4 (0.5) | 1.4 (0.5) | 1.3 (0.4) | 1.2 (0.5) | 1.2 (0.5) |
% predicted | 46.7 (12.8) | 47.3 (12.9) | 47.0 (12.8) | 45.9 (12.8) | 44.9 (13.5) | 45.4 (13.2) |
Post-bronchodilator FEV1, mean (SD) | ||||||
Volume, L | 1.6 (0.5) | 1.6 (0.5) | 1.6 (0.5) | 1.5 (0.5) | 1.4 (0.5) | 1.4 (0.5) |
% predicted | 55.5 (12.9) | 56.3 (12.7) | 55.9 (12.8) | 53.2 (13.5) | 52.7 (13.6) | 53.0 (13.5) |
FVC, L, mean (SD) | ||||||
Pre-bronchodilator | 2.6 (0.9) | 2.7 (0.9) | 2.7 (0.9) | 2.6 (0.8) | 2.5 (0.8) | 2.6 (0.8) |
Post-bronchodilator | 3.1 (0.9) | 3.1 (0.9) | 3.1 (0.9) | 2.9 (0.9) | 2.9 (0.9) | 2.9 (0.9) |
FEV1/FVC, % | ||||||
Pre-bronchodilator | 50.9 (10.2) | 50.8 (9.9) | 50.8 (10.0) | 48.9 (11.0) | 47.1 (10.7) | 48.0 (10.8) |
Post-bronchodilator | 52.2 (10.2) | 52.3 (9.8) | 52.2 (10.0) | 50.4 (11.1) | 49.1 (10.8) | 49.8 (10.9) |